Study title:
A single arm Phase I/II study of the safety and efficacy of gene-modified WT1 TCR therapy in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)
Date receipt dossier:
20 Aug 2015
EudraCT number:
2014-003111-10
Company / Sponsor:
Catapult Cell Therapy
Phase:
I/II
Treated organism:
Humans
Indication category:
Cancer therapy
Disease:
Acute myeloid leukemia and myelodysplastic syndromes in adults
Therapeutic approach:
Immunotherapy
Genetic modification:
Expression of the Wilms' tumour antigen 1 (WT1)- specific T cell receptor (TCR)
Method of transfer of nucleic acid of interest:
Retroviral vectors
Administered biological material:
Autologous T-cells transduced with retroviral vectors expressing WT1-specific TCR
Route of administration:
Intravenous
Locations in Belgium:
UZ Leuven, AZ Sint-Jan Brugge-Oostende
Type of procedure:
Contained use only
Current status:
Authorized